Skip to main contentSkip to navigation
Sirius Investors

ALZCUR.ST Stock: AlzeCure Pharma AB (publ) Stock Price, Analysis & Insights

Get live ALZCUR.ST stock price $4.28, comprehensive AlzeCure Pharma AB (publ) stock analysis, charts, news, and expert forecast. Real-time ALZCUR.ST stock data and investment insights.

4.28
8.08%Today
ALZCUR.STAlzeCure Pharma AB (publ) • Stockholm Stock Exchange • Healthcare
Market Cap
561.89M
Volume
1.34M
52W High
5.69
52W Low
1.16

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

AlzeCure Pharma AB (publ) is a pharmaceutical firm focused on pioneering drug treatments for debilitating conditions impacting the central nervous system (CNS). The company's pipeline of potential medicines is rooted in three distinct research platfo...

Company Information

CEO
Martin Jönsson
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
11

Contact Information

Address
HAelsovAegen 7
Country
SE

Investment Analysis & Business Insights

Healthcare
Drug Manufacturers - Specialty & Generic

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: -0.07) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for AlzeCure Pharma AB (publ) shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for AlzeCure Pharma AB (publ)
  • Investors should consider how AlzeCure Pharma AB (publ) fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

561.89M

P/E Ratio (TTM)

-8.92

Beta

-0.07

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

43/100 ⭐⭐⭐

Overall
-1.0%
NYSE
-1.6%
NASDAQ
-0.4%
Sector1D1W1MP/EScore
Financial Services+0.3%+1.3%+1.9%19.8
83/100⭐⭐⭐⭐⭐
Technology+0.8%+1.1%+3.0%52.0
76/100⭐⭐⭐⭐⭐
Basic Materials+0.8%+0.3%+1.9%27.9
69/100⭐⭐⭐⭐
Industrials-0.3%-0.9%+2.7%43.0
64/100⭐⭐⭐⭐
Communication Services-0.8%-1.3%+0.4%21.9
48/100⭐⭐⭐
Consumer Defensive+0.6%+1.6%-2.5%31.2
44/100⭐⭐⭐
Healthcare-1.0%-2.0%+1.5%30.5
43/100⭐⭐⭐
Real Estate+0.5%-1.1%-0.0%50.0
33/100⭐⭐
Energy+0.5%-3.6%-0.0%35.9
31/100⭐⭐
Utilities+2.0%-1.3%-5.1%26.1
31/100⭐⭐
Consumer Cyclical-0.3%+0.3%-0.2%55.8
28/100⭐⭐

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-06-13.